Regenerative Medicine for Orthopedics

More than 500 million people worldwide live with osteoarthritis, a degenerative joint disease that causes severe, debilitating pain and often requires surgery or joint replacement. Cedars-Sinai is pioneering breakthroughs in regenerative medicine that offer hope for far less invasive and nonsurgical procedures for treating the condition.

By
January 15, 2025
6 min

Cedars-Sinai Pulse

At a Glance

Category	Detail
Condition	Osteoarthritis and musculoskeletal injuries
Key Mechanisms	Stem cell therapy and platelet-rich plasma (PRP) injections to reduce inflammation, promote healing, and regenerate tissue.
Target Population	Individuals with osteoarthritis and tendon/ligament injuries, particularly older adults and athletes.
Care Setting	Orthopedic clinics and regenerative medicine institutes.

Key Highlights

Over 500 million people globally are affected by osteoarthritis.
Regenerative medicine aims to provide less invasive treatments for joint pain and injuries.
Induced pluripotent stem cells (iPSCs) are being developed to regenerate damaged discs and tendons.
Platelet-rich plasma (PRP) therapy is gaining popularity but lacks extensive scientific validation.
Collaborative research is underway to analyze PRP samples from 1,000 patients.

Guideline-Based Recommendations

Diagnosis

Utilize advanced imaging techniques to identify sources of pain.
Develop biomarkers for more accurate diagnosis of discogenic pain.

Management

Consider regenerative therapies such as iPSC and PRP injections for osteoarthritis and tendon injuries.
Implement biobehavioral tests to assess treatment efficacy.

Monitoring & Follow-up

Conduct larger studies to evaluate the effectiveness of PRP components.
Monitor patient outcomes post-treatment to refine therapeutic approaches.

Risks

Potential adverse effects from certain immune cells in PRP.
Risk of re-tearing in surgically repaired tendons due to fibrosis.

Patient & Prescribing Data

Adults with osteoarthritis, particularly those with knee involvement and athletes at risk for knee injuries.

iPSCs may prevent later-onset arthritis if administered post-injury.

Clinical Best Practices

Focus on developing a family of orthobiologics to improve patient outcomes.
Utilize a multidisciplinary approach in research and treatment development.
Encourage participation in clinical trials to advance regenerative medicine applications.